LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, reported financial results for the second ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

LANGHORNE, Pa.--(BUSINESS WIRE)-- Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the pricing of an underwritten offering ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

In response to favorable analyst coverage, shares of Savara (NASDAQ: SVRA), a clinical-stage biotech focused on rare lung diseases, soared 23% as of 12:10 p.m. EDT on Friday. Savara's investors can ...

Savara ( (SVRA)) has issued an update. On June 4, 2026, Savara’s stockholders approved an amendment to the 2024 Omnibus Incentive Plan, increasing the pool of shares available for equity awards by 18, ...

The big shareholder groups in Savara Inc. (NASDAQ:SVRA) have power over the company. Institutions will often hold stock in bigger companies, and we expect to see insiders owning a noticeable ...

SAN DIEGO, Sept. 24, 2025 /PRNewswire/ -- Robbins LLP reminds stockholders that a class action was filed on behalf of persons and entities that purchased or otherwise acquired Savara Inc. (NASAQ: SVRA ...

Good day and welcome to the Savara conference call. At this time, all participants are in a listen-only mode. An audio webcast of this call will be available on the Investors section of Savara's Web ...

Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the pricing of an underwritten public offering of 23,809,524 shares of its ...